We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Testing Evaluated for Chlamydia and Gonorrhea

By LabMedica International staff writers
Posted on 23 Nov 2016
Prolonged turnaround time of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) test results may delay time to notification and treatment of test-positive patients and result in unnecessary antimicrobial use in test-negative patients.

Nonculture methods, including nucleic acid amplification tests (NAAT), are widely available for the detection of genital NG/CT and are the preferred diagnostic tests, but with traditional NAAT, many health care facilities have a turnaround time between 1 and 4 days for results of NG/CT. More...
This prolonged time to results impacts time to patient and partner notification as well as treatment for test-positive patients who do not receive empiric therapy.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) and their colleagues evaluated the impact of NG/CT rapid diagnostic testing (RDT) in an urban emergency department (ED) on treatment appropriateness, time to notification, and cost. They tested 200 patients in December 2013–January 2014 by traditional methods and these were compared with 200 patients in December 2014–January 2015 by RDT. Samples utilized by the ED included male urine or urethral samples and female endocervical samples.

Traditional testing was performed using the Gen-Probe Aptima Combo 2 for NG/CT Assay (Hologic, Bedford, MA, USA). The RDTs were performed using the GeneXpert CT/NG assay (Cepheid, Sunnyvale, CA, USA). The RDT was validated compared with the traditional testing method with sensitivity and specificity. A total of 53 patient specimens were collected and tested including male and female first-catch urine samples, patient-collected vaginal swabs, and provider-collected endocervical swabs.

The scientists found that there was a significant increase in treatment appropriateness in the RDT group, 72.5% versus 60% and time to results notification was significantly faster with a median of 17.4 versus 51.5 hours. Availability of test result prior to discharge was associated with increased treatment appropriateness. They also reported that the RDT would save approximately USD 37,000 annually. Of the 200 patients tested in the RDT group, only 40 (20%) were present in the ED at the time their results became available.

The authors concluded that implementation of a RDT for NG/CT in the ED significantly improved initial treatment appropriateness by sparing unnecessary antimicrobial use, decreased time to patient notification, and resulted in cost savings. Having test results prior to patient discharge from the ED was independently associated with receiving appropriate treatment. Interventions to increase the proportion of tests resulted prior to discharge are warranted to improve utilization of the RDT. The findings of this evaluation support the use of the NG/CT RDT as a component of antimicrobial stewardship in the ED. The study was published on October 18, 2016, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Cleveland Clinic
Hologic
Cepheid

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.